Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

314 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lymphocytic panhypophysitis and anti-rabphilin-3A antibody with pulmonary sarcoidosis.
Takahashi Y, Kameda H, Miya A, Nomoto H, Cho KY, Nakamura A, Nishimura H, Kimura H, Suzuki M, Konno S, Shimizu A, Matsuno Y, Okamoto M, Motegi H, Iwata N, Fujisawa H, Suzuki A, Sugimura Y, Miyoshi H, Atsumi T. Takahashi Y, et al. Among authors: miya a. Pituitary. 2022 Apr;25(2):321-327. doi: 10.1007/s11102-021-01200-0. Epub 2022 Jan 28. Pituitary. 2022. PMID: 35088194 Free article.
Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial.
Miya A, Nakamura A, Miyoshi H, Cho KY, Nagai S, Kurihara Y, Aoki S, Taguri M, Terauchi Y, Atsumi T. Miya A, et al. J Diabetes Investig. 2018 Jan;9(1):119-126. doi: 10.1111/jdi.12654. Epub 2017 Jul 10. J Diabetes Investig. 2018. PMID: 28296201 Free PMC article. Clinical Trial.
The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3).
Kitao N, Miyoshi H, Furumoto T, Ono K, Nomoto H, Miya A, Yamamoto C, Inoue A, Tsuchida K, Manda N, Kurihara Y, Aoki S, Nakamura A, Atsumi T; SAIS Study Group. Kitao N, et al. Among authors: miya a. Cardiovasc Diabetol. 2017 Oct 10;16(1):125. doi: 10.1186/s12933-017-0607-6. Cardiovasc Diabetol. 2017. PMID: 29017497 Free PMC article. Clinical Trial.
Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial.
Takase T, Nakamura A, Yamamoto C, Nomoto H, Miya A, Dannoura M, Cho KY, Kurihara Y, Manda N, Aoki S, Atsumi T, Miyoshi H. Takase T, et al. Among authors: miya a. J Diabetes Investig. 2019 May;10(3):699-705. doi: 10.1111/jdi.12906. Epub 2018 Sep 19. J Diabetes Investig. 2019. PMID: 30076787 Free PMC article. Clinical Trial.
Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes.
Takahashi K, Cho KY, Nakamura A, Miya A, Miyoshi A, Yamamoto C, Nomoto H, Niwa H, Takahashi K, Manda N, Kurihara Y, Aoki S, Ito YM, Atsumi T, Miyoshi H. Takahashi K, et al. Among authors: miya a. J Diabetes Investig. 2019 Mar;10(2):429-438. doi: 10.1111/jdi.12913. Epub 2018 Sep 26. J Diabetes Investig. 2019. PMID: 30136403 Free PMC article.
Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial.
Cho KY, Nakamura A, Omori K, Takase T, Miya A, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. Cho KY, et al. Among authors: miya a. Diabetes Obes Metab. 2019 Mar;21(3):710-714. doi: 10.1111/dom.13557. Epub 2018 Nov 8. Diabetes Obes Metab. 2019. PMID: 30311367 Free PMC article. Clinical Trial.
314 results